For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.
Treatment Study for Patients with Localized Central Nervous System Germ Cell Tumors
To determine, as measured by the 3-year progression free survival rate and patterns of failure, whether simplified chemotherapy followed by dose-reduced radiation therapy is effective for treating children and young adults (ages 3 to < 21 years) with localized primary central nervous system (CNS) germinoma who present with serum and/or CSF human chorionic gonadotropin-beta (hCGI3) < 50miU/ml.
In order to participate you must meet the following criteria:
- Are between 3 and 21 years of age at the time of study enrollment.
- Have been newly diagnosed with localized primary CNS NGGCT (Stratum 1) or localized primary CNS germinoma (Stratum 2). Germ cell tumors located in the suprasellar pineal, bifocal (pineal + suprasellar) and ventricles are eligible. Tumors present in the above mentioned locations and with unifocal parenchymal extension are eligible.
This is a partial list of elgibility requirements.